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A B S T R A C T   
Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the 
benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have 
been proposed in the literature, many of which have been adopted in practice. 
Implementing such trial designs in practice can be challenging, and identifying those challenges was the main 
objective of a workshop organised by the MRC Hubs for Trials Methodology Research Network’s Stratified 
Medicine Working Group in March 2017. Participants reflected on completed and ongoing biomarker-guided 
trials to identify the practical challenges encountered. Here, the key challenges identified during the work-
shop including those related to funding, ethical and regulatory issues, recruitment, monitoring of samples and 
laboratories, biomarker assessment, and data sharing and resources, are discussed. 
Despite the complexities often associated with biomarker-guided trials, the workshop concluded that they can 
play an important role in advancing the field of personalised medicine. Therefore, it is important that the 
practical challenges surrounding their implementation are acknowledged and addressed.   
1. Introduction 
Clinical trials are essential for testing the safety and efficacy of new 
treatments. Increasingly, biomarkers are becoming an integral part of 
clinical trials as they are considered key tools in the identification of 
patient sub-populations most likely to benefit or conversely to incur 
adverse reactions from a given treatment. Hence, so-called biomarker- 
guided trial designs are pivotal in advancing the field of personalised 
medicine which aims to give ‘the right treatment to the right patient, at 
the right dose at the right time’ [1,2]. Consequently several 
biomarker-guided trial designs which test the effectiveness of a 
biomarker-guided approach to treatment have been proposed in the 
literature, some of which have been adopted in practice. Detailed re-
views of biomarker-guided designs have been published [3–6] and are 
also available via an online tool “BiGTeD” (http://www.bigted.org/). 
A one-day workshop organised by the MRC Hubs for Trials Meth-
odology Research Network’s Stratified Medicine Working Group 
(SMWG) was held in London in March 2017. The aim was to identify and 
explore the key practical challenges arising when conducting a 
biomarker-guided clinical trial. The workshop brought together 25 
participants with practical experience in conducting biomarker-guided 
trials from various disciplines including statisticians, trial managers, 
information systems specialists and clinicians. This workshop was 
motivated by feedback from trialists and previous literature [3,4] sug-
gesting that there are substantial challenges associated with undertaking 
trials adopting these types of designs. 
Specific trials were utilised as exemplars to aid discussion and these 
are the focus of the first part of this paper. The second part provides an 
overview of the practical challenges raised at the workshop and iden-
tified from delegates’ experiences, together with some of our own re-
flections on those issues from our methodology reviews and simulation 
studies [3,4,7]. Issues considered include funding, ethical and regula-
tory issues, recruitment, monitoring of samples and laboratories, 
biomarker assessment, data sharing, and resourcing. A summary table is 
also provided of each trial’s key characteristics with examples of some of 
the challenges they faced (Table 1). 
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2. Biomarker-guided trials used as exemplars 
The majority of trials discussed at the workshop are oncology trials 
simply because oncology dominates the field of personalised medicine. 
Many of the challenges identified apply equally to trials in other clinical 
areas.  
i) The National Lung Matrix Trial (NLMT; ongoing trial) [8]: 
This is a phase II non-randomized umbrella trial consisting of 
multiple single arm trials within one protocol. The aim of the trial 
is to investigate a range of new treatments hypothesized to be of 
benefit to specific molecularly-defined cohorts of patients with 
advanced non-small cell lung cancer (NSCLC) and for whom 
surgery and radiotherapy are not deemed appropriate treatments. 
NLMT runs alongside the Cancer Research UK Stratified Med-
icine Programme (SMP2), where a next generation sequencing 28 
gene panel test is used to assess the genetic profile of trial par-
ticipants which then determines which single arm trial (strata), 
and hence drug, they are assigned to. The trial adopts a Bayesian 
adaptive design with an interim analysis at 15 patients for each 
strata and final analysis of a target group of 30 patients per strata. 
The trial was designed to evaluate a common set of outcome 
measures with primary outcome measures chosen specifically for 
each treatment arm. A clinically relevant signal of efficacy is 
defined: for cytostatic agents as median progression-free survival 
greater than 3 months; for other agents as rates of objective 
response [19] or durable clinical benefit (defined as remaining 
free of disease progression at a CT or MRI scan approximately 24 
weeks after starting treatment, or thereafter) with a critical 
cut-off greater than 30% for single agent and 40% for combina-
tion therapy arms. 
ii) Phase II trial of olaparib in patients with advanced castra-
tion resistant prostate cancer (TOPARP) (ongoing at time of 
workshop, now closed to recruitment) [9]: This is an open 
label, phase II, single arm, 2 part adaptive design trial for 
biomarker-driven selection based on response rate. It aims to 
evaluate the anti-tumour activity of the Poly (ADP-ribose) poly-
merase (PARP) inhibitor, olaparib, in metastatic castration 
resistant prostate cancer (mCRPC) and to identify molecular 
signatures for PARP inhibitor sensitivity with a pre-planned 
analysis to identify a biomarker-defined sensitive subgroup. In 
the first part unselected (i.e. without biomarker-guided patient 
selection) mCRPC patients are all treated with olaparib. If during 
the first part the response rate is high (i.e.,  50% responding) the 
trial will close and a randomized placebo controlled clinical trial 
to evaluate the efficacy and safety of olaparib in these unselected 
mCRPC patients is undertaken. If the response rate is low (i.e. 
response rate <10%), the trial is stopped. If in the intermediate 
range (10–50% responding), potential biomarkers of response are 
investigated and if a potential biomarker is identified, with those 
positive for the biomarker having a high response rate (50%), 
the trial continues to the second part where only biomarker 
selected patients are included.  
iii) Adaptive multi-arm phase II trial of maintenance targeted 
therapy after chemotherapy in metastatic urothelial cancer 
(ATLANTIS) (ongoing) [10]: This is an adaptive multi-arm 
randomized phase II trial which aims to explore whether main-
tenance targeted therapy after chemotherapy, with treatment 
randomisation based on biomarker profile, delays time to pro-
gression and increases overall survival for patients with advanced 
urothelial cancer. The initially planned biomarker is androgen 
receptor status with patients who are androgen receptor positive 
randomised between enzalutamide and placebo. The “adaptive” 
element of ATLANTIS is the ability to add comparisons in other 
biomarker selected subgroups (for example a comparison of 
rucaparib v placebo is planned in patients who have BRCA1 or 
BRCA2 mutations, either as a somatic or germline event, or with 
evidence of homologous recombination deficiency).  
iv) PRIMUS001 (ongoing) [11]: This is an adaptive phase II trial, 
with biomarker evaluation integrated into the trial which aims to 
assess the efficacy of FOLFOX-A (FOLFOX and nab-paclitaxel) 
when compared to AG (nab-paclitaxel and gemcitabine) in pa-
tients with metastatic pancreatic cancer, both in a 
biomarker-positive group and in biomarker-unselected patients. 
PRIMUS001 will determine whether there is a benefit from 
FOLFOX-A compared to AG, and if there is a benefit whether this 
is in all patients or in biomarker  ive patients only. As the study 
proceeds there are a number of interim analyses following which 
subsequent recruitment may be restricted to biomarker  ive 
patients if there is no evidence of benefit of FOLFOX-A compared 
to AG in biomarker unselected patients.  
v) SALONICA (planned trial): This is a stratified adaptive trial in 
ovarian cancer aiming not only to detect the key genomic de-
terminants of response and resistance to neoadjuvant platinum- 
base chemotherapy in high-grade serous ovarian cancer but 
also to identify and validate putative biomarkers as well as test 
several novel drugs and corresponding putative biomarkers in 
women with poor response to neoadjuvant platinum chemo-
therapy through a phase II trial platform. SALONICA is initially 
based on a sequence of single-arm biomarker unselected phase II 
designs, but as information on the mutational changes and 
associated biomarkers in ovarian cancer accumulates the ambi-
tion is to move to a design based on Bayesian Adaptive Ran-
domisation (BAR).  
vi) TASTER (planned trial): This trial aims to identify predictors of 
response to novel combination therapies in Chronic Myeloid 
Leukaemia (CML) patients who do not respond to tyrosine kinase 
inhibitor therapy. Both in vivo models of drug response and 
clinical data will be used to identify molecular signatures of stem 
cell resistance and build and validate predictive models of drug 
response from which the best treatment for a patient can be 
selected. The success of the predictive model will be assessed in a 
standard single arm phase II design for each candidate novel 
combination. 
vii) POETIC (Peri-Operative Endocrine Therapy for Individual-
izing Care) (ongoing trial) [12,13]: This is a randomized, 
multicentre phase III trial which aims to investigate whether 
having perioperative aromatase inhibitor (AI) therapy for post-
menopausal women with ER/PgR positive invasive breast 
cancer is more effective than having standard care alone. 4,476 
patients were recruited from 130 UK centres. Patients received 
either AI therapy for 4 weeks (two weeks before and two weeks 
after surgery) or no peri-operative AI therapy. Whilst ER is a well 
established biomarker it is not usually used to direct therapy so 
early in the patient pathway, thus new procedures had to be 
established for the trial to ensure its measurement was available 
at the time of diagnosis based on a core biopsy.  
viii) FOCUS4 trial (ongoing trial) [14]: This is an umbrella clinical 
trial consisting of parallel, molecularly stratified randomized 
comparisons in patients with metastatic colorectal cancer 
(mCRC). Patients with newly diagnosed mCRC are registered into 
the trial and commence their standard first line chemotherapy 
which typically lasts for approximately 16 weeks. During this 
time, a sample of their tumour is sent away to one of two dedi-
cated FOCUS4 laboratories who perform genomic and molecular 
tests on the tumour. This enables stratification of the patients into 
one of a number of pre-specified molecular subgroups (called 
cohorts). Patients are then offered entry into a randomized trial 
(called comparison) testing a specific targeted therapy for their 
subtype of cancer. All these comparisons are randomized and 
controlled and wherever possible use a placebo in the control 
group. 
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Table 1 
Summary of each trial’s key characteristics.  
Trial Disease Primary 
endpoint(s) 
Number of 
arms 
Trial design Type of 
biomarker(s) 
Role of 
biomarker(s) 
Responsibility 
for overall 
management 
Primary 
funding 
source(s) 
Challenges 
NLMT Advanced non- 
small cell lung 
cancer 
Best 
objective 
response; 
Durable 
clinical 
benefit; 
Progression- 
free survival 
time 
8 Bayesian 
adaptive 
umbrella 
design 
Genetic 
markers 
To determine 
arm/treatment 
allocation 
Early Drug 
Development 
(EDD) Trial 
Management 
Team based 
within the 
Cancer 
Research UK 
Clinical Trials 
Unit (CRCTU), 
University of 
Birmingham 
Cancer 
Research UK 
Uncertainty 
regarding total 
costs of trial – 
resolved by 
submitting 
estimated 
future costs 
and CRUK 
providing 
agreement in 
principle; 
additional 
costs of 
biomarker 
analysis – 
resolved by 
funding 
molecular 
screening 
platform as 
separate entity; 
significant 
dropout due to 
recruiting 
patients with 
advanced 
disease; CTU 
personnel 
required to 
interpret 
biomarker 
reports 
themselves to 
determine 
relevant 
treatment arm 
TOPARP Metastatic 
castration 
resistant prostate 
cancer 
Treatment 
response 
according to 
pre- 
specified 
criteria 
TOPARP-A: 
single arm 
TOPARP-B: 
two-arm 
randomised 
TOPARP- A: 
Open-label, 
single arm, 
two part 
adaptive 
design phase 
II trial. 
TOPARP-B: 
Open-label, 
two-arm 
randomised, 
each arm 
with a single 
stage phase II 
design. 
Genetic 
markers 
TOPARP-A: 
Biomarker 
development - 
to identify 
predictive 
biomarkers of 
response to 
olaparib 
TOPARP B: 
Biomarker 
validation - 
biomarker 
guided patient 
selection for 
eligibility to 
confirm sub- 
group 
identified in A 
Institute of 
Cancer 
Research, UK 
Trial run 
under the 
NCRN-AZ 
initiative 
(CRUK and 
AZ funded) 
Complex 
sampling 
collection and 
processing 
requirements 
outside 
standard 
pathway at 
sites. QA 
sample failures 
at central labs 
which lead to 
delays in 
biomarker 
results being 
available; 
Greater CTU 
and lab 
activity/ 
resource 
required to 
manage 
challenges and 
ensure 
collaborators’ 
expectations 
were met. 
ATLANTIS Metastatic 
urothelial cancer 
Progression- 
free survival 
3 Adaptive 
multi-arm 
design 
Homologous 
recombination 
deficiency and 
genetic 
markers 
To determine 
arm/ 
randomisation 
treatment 
Clinical Trials 
Unit, 
University of 
Glasgow 
Cancer 
Research UK  
PRIMUS001 Metastatic 
pancreatic cancer 
Progression- 
free survival 
2 Adaptive 
design 
Genetic 
markers 
For subgroup 
analysis of 
primary 
outcome, and 
Clinical Trials 
Unit, 
University of 
Glasgow 
Cancer 
Research UK  
(continued on next page) 
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Table 1 (continued ) 
Trial Disease Primary 
endpoint(s) 
Number of 
arms 
Trial design Type of 
biomarker(s) 
Role of 
biomarker(s) 
Responsibility 
for overall 
management 
Primary 
funding 
source(s) 
Challenges 
to determine 
eligibility for 
recruitment 
following 
interim 
analyses 
SALONICA Ovarian cancer Progression- 
free survival 
1 Sequence of 
single arm 
trials, but 
plans to 
progress to 
Bayesian 
adaptive 
randomised 
design 
Genetic 
markers 
Initially for 
subgroup 
analysis, and 
then to 
determine 
randomisation 
ratio 
Clinical Trials 
Unit, 
University of 
Glasgow 
N/A – 
planning 
stage  
TASTER Chronic Myeloid 
Leukaemia 
Progression- 
free survival 
1 Series of 
single arm 
trials 
Biomarkers 
contributing to 
molecular 
signatures 
To determine 
eligibility for 
which single 
arm trial 
Clinical Trials 
Unit, 
University of 
Glasgow 
N/A – 
planning 
stage  
POETIC Breast cancer Relapse free 
survival 
2 Two-arm 
parallel 
randomised 
controlled 
trial 
Genetic marker 
and Gene 
expression 
profile 
To determine 
eligibility and 
for subgroup 
analyses 
Institute of 
Cancer 
Research, UK 
Cancer 
Research UK  
FOCUS 4 Metastatic 
colorectal cancer 
Progression- 
free survival 
3 
molecularly 
stratified 
trials and 1 
non- 
stratified 
trial 
Multi-arm, 
multi-stage 
umbrella 
design 
Genetic 
markers 
To determine 
arm/ 
randomisation 
treatment 
MRC Clinical 
Trials Unit at 
UCL 
NIHR/MRC 
EME 
Programme 
and Cancer 
Research UK 
Intensive CTU 
resource 
requirements 
for the multi- 
tasking aspects 
of the adding 
and dropping 
arms design;  
High costs of 
running trial – 
resolved by 
securing joint 
funding 
between MRC/ 
NIHR EME and 
Cancer 
Research UK 
and having 
trial conducted 
in a CTU with 
separate core 
funding;  
Delays in 
biomarker 
results 
turnaround 
and failed 
samples; 
Pathology 
number 
discrepancies; 
Failure to send 
GCP compliant 
documents 
from pathology 
lab to CTU;  
Needing 
comparison- 
specific CRFs 
therefore sites 
having to deal 
with several 
separate 
databases; 
EU-PACT Atrial fibrillation 
and venous 
thromboembolism 
Time in 
therapeutic 
INR range 
during first 
three 
2 Two-arm 
parallel 
randomised 
controlled 
trial 
Genetic 
markers 
Predict 
therapeutic 
dose 
Wolfson Centre 
for 
Personalised 
Medicine, 
University of 
Liverpool 
European 
Commission 
Seventh 
Framework 
Programme 
Need for rapid 
turnaround of 
genotyping 
results to allow 
same-day 
treatment 
(continued on next page) 
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ix) EU-PACT trial (completed trial) [15]: This was a pragmatic, 
single-blind, randomised controlled trial to determine whether 
genotype-guided dosing of the anticoagulant warfarin is superior 
to standard dosing. Patients commencing warfarin were rando-
mised to one of two trial arms. Those randomised to the 
genotype-guided dosing arm had their genotype tested at three 
genetic variants using a point of care test, with results available 
within 2 h. Their genotype was fed into a computer based loading 
dose algorithm, together with demographic and clinical infor-
mation, and a personalised loading dose recommended for the 
first three days. Similar information was then fed into a mainte-
nance dose algorithm to determine dose on days 4 and 5 of 
treatment. From day 6 dosing was according to standard clinical 
care. Those randomised to the control arm had their loading and 
subsequent doses calculated according to standard approaches, 
with no reference to genotype. All patients were followed up for 
three months and their anticoagulation control assessed. 
3. Challenges 
3.1. Funding issues 
Biomarker-guided trials often have a complex design – both scien-
tifically and logistically and it is therefore not surprising that the re-
sources required are typically considerably higher than for trials with 
more simple designs. Nonetheless, funders show substantial enthusiasm 
for supporting biomarker-guided trials, since it is recognised that despite 
increased costs the trial may well be more efficient in demonstrating 
patient benefit. When considering the additional resources required, the 
increased administrative burden is a major factor: for instance, in um-
brella type designs necessary documentation and multiple approvals 
need to be repeated for each treatment group of the trial. How those 
amendments are handled (e.g. the addition of a new trial group), can 
depend on cost. For example, it is typical for changes that don’t require 
additional funding from charitable or public bodies (generally where 
funding is provided by a pharmaceutical partner) to be implemented 
quickly without additional approvals, but if the amendment is likely to 
require additional funding support then it is necessary for it to go 
through the more classic route of peer-review and research grant 
approval. 
Further, despite the attractive flexibility they bring, by virtue of their 
design the overall costs of adaptive trials in particular are difficult to 
predict at the outset due to the uncertainty surrounding their future 
direction, for example the number of additional/discontinued groups 
and final sample size. In addition, with science evolving at such a fast 
pace, biomarker assessment costs may change with changing technolo-
gies. Open communication between those involved in planning such a 
trial and funders is important from the outset to determine the best way 
to handle applying for funding. Such open communication will also help 
inform funders on the implications of using such designs for their 
funding streams. 
So that overall costs can be considered, and to avoid triggering 
further full processes for committee approval with the addition of each 
new trial group, it can be advantageous for applicants to provide details 
on potential additions at the outset to allow funders to forecast and 
earmark the foreseeable additional budget and provide approval in 
principle. A similar agreement is already in place with CRUK for NLMT. 
So, a researcher putting an application for an umbrella trial, for example 
to include initial trial groups A to D, would be required to also estimate 
how much it would cost to add groups E, F, and G at time points X,Y and 
Z. Understandably, providing such predictions of future costs can be 
difficult as it requires knowledge not only of the approximate size of the 
trial groups to be added (or indeed removed) within those changes, but 
also the time point at which they will be added and the approximate end 
date. 
Further, including additional forecasted costs could easily make a 
trial unattractive to funders, with projected total costs for a large trial 
using up the entire budget for a funding call. Funders will always be 
faced with many competing funding requests, many of which will have 
simpler and easier to understand designs and more transparent budgets. 
It is anticipated however that once many of the currently ongoing 
trials are completed, there will be a better understanding of the value for 
money offered by such trial designs. However it is important to note that 
this could be misleading in itself since it is widely recognised in the trial 
community that many such trials may have been significantly under- 
resourced. Quite often, it is the Clinical Trial Units (CTU) costs (e.g. 
trial management, trial monitoring, statistical analysis and oversight) 
that are compromised. 
One possible model is to fund the molecular screening platform as a 
separate venture from the trial itself and run them as two interrelated 
studies. This can be seen in NLMT where the Stratified Medicine Pro-
gramme 2 (SMP2) provides a comprehensive screening programme 
funded by Cancer Research UK in collaboration with pharmaceutical 
partners and the NLMT is funded as a separate Cancer Research UK trial 
grant. SMP2 provides the patients for NLMT so the success of the trial is 
entirely predicated on the success of SMP2 and clearly close interaction 
between the two separate projects is essential. Such a funding model can 
be appropriate if the stratifying biomarkers involved are novel and 
outside of routine testing and provides transparency in terms of the costs 
for the two major elements in such a trial. 
FOCUS4 provides an example of how exploring alternative funding 
arrangements led them to successfully securing funding for their trial. 
Joint funding was applied for between CRUK and the Efficacy and 
Mechanism Evaluation (MRC/NIHR EME) Programme. Every time a 
new cohort is added an EME Sub Board meeting is held with represen-
tatives from CRUK and EME. A scientific rationale and funding model 
has to be presented by the investigators to this Sub Board for scrutiny. 
This approach has worked well and could be a viable option for similar 
trials as long as the funding bodies are encouraged by the efficiencies 
and opportunities of joint long-term commitments. 
There has also been some confusion amongst researchers in the UK 
about who should fund the additional biomarker tests within a trial. It 
has previously been suggested that this is a National Health Service 
(NHS) cost since it is used to direct treatment, however since the test is 
Table 1 (continued ) 
Trial Disease Primary 
endpoint(s) 
Number of 
arms 
Trial design Type of 
biomarker(s) 
Role of 
biomarker(s) 
Responsibility 
for overall 
management 
Primary 
funding 
source(s) 
Challenges 
months of 
treatment 
initiation at 
predicted dose 
– resolved by 
working with 
industrial 
collaborator to 
develop 
efficient point 
of care test  
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often unavailable on the NHS, it could be considered to be a research 
cost. Another viewpoint is that, in the case of a test not yet implemented 
in practice, if the cost of the test in a research setting exceeds the hy-
pothetical cost of using the test in routine practice, the additional cost 
should be covered by research funding, with the hypothetical costs 
associated with using the test in practice, being classed as (potentially 
excess) treatment costs. This situation may be slowly changing, how-
ever, as we move into an era where more biomarker tests are routinely 
undertaken in practice. 
Finally, an additional funding issue relates to whether the trial uses 
previously untested biomarkers or more established and validated ones; 
the former may incur additional costs for the development, validation 
and standardization of appropriate assays, and delays in the expected 
start date. Further, issues with sample quality can cause problems for 
recruitment in situations where results are required with a tight turn-
around, as can problems with the assay e.g. its sensitivity. 
In summary, detailed and early planning with clear communication 
between researchers and funders is vitally important to ensure that 
future trials can be fairly considered and appropriately funded. There is 
also room for learning, with those with practical experience of such 
trials sharing their knowledge and experiences with funding bodies as 
well as funding bodies, with their broader oversight across a spectrum of 
trials that they fund, sharing the same with researchers. These trials can 
appear overwhelming if viewed within the classical approvals paradigm 
but are not as complicated as is often believed. With some designs, they 
can be considered as a collection of individual separate trials with some 
additional biomarker analyses. If their benefits and limitations are 
communicated effectively, then they should be embraced rather than 
feared. 
3.2. Ethical and regulatory issues 
A key issue here is the different ways in which regulatory bodies 
choose to classify a biomarker-guided trial. For instance, there is an 
expectation that when adding a new Investigational Medicinal Product 
(IMP) to an umbrella trial there should also be a new CTA (Clinical Trial 
Authorization), which may not necessarily be required. Consideration 
needs to be given to the subtleties of adding a new IMP, for example if it 
comes from a different class of drugs than existing IMPs and with a 
different safety profile and changes the scientific intent of the trial a new 
CTA may be entirely appropriate, whilst unnecessary with more similar 
IMPs. It may also be believed that from a commercial perspective the 
trial will be testing, developing and marketing a companion diagnostic 
alongside the therapeutic, which is not always the case. Early discussion 
with the competent authority is strongly advised. 
Although the general consensus is that research ethics committees 
view these types of trials very positively, many ongoing administrative 
issues need to be addressed. Whilst an ethics committee might give 
overall ethics approval at the outset, it is often not clear how the addi-
tion of new trial groups will be approved later. Depending on local 
practice, amendments may not be reviewed, discussed and approved by 
a sub-committee; or may even come through simply as a chairman’s 
action. Consequently, the trial documents are perhaps not checked in the 
same way as the original application and the amendments may not 
receive the same level of scrutiny. In addition, there is inconsistency in 
what documentation ethics committees request for amendment 
approval, with some requesting a new submission and others seeking a 
major amendment. It is important that a collaborative relationship is 
maintained with the Health Research Authority (HRA) to ensure that 
administrative systems, paperwork, and version control are adapted to 
adequately deal with these types of amendments. Researchers with 
experience of running such trials are well placed to advise in this regard. 
Similar collaborative relationships also need to be maintained with 
the relevant regulatory authority (e.g. the Medicines and Healthcare 
products Regulatory Agency (MHRA) or EMA or FDA). For example, the 
name of a trial’s CTA is based on the initial treatment drugs included in 
the trial; however, these may not be part of the trial for the whole 
duration of the trial (e.g. due to ineffective treatment groups being 
dropped and other promising ones being added) which can lead to 
confusion in terms of terminology. 
From the perspective of patients, some issues need to be considered 
relating to the informed consent process. There are examples of having 
to consent patients into the trial on the same day of diagnosis, for 
example so that a sample can be sent immediately for biomarker testing 
to avoid delaying treatment down the line, which clearly requires both 
careful and appropriate communication. Another issue could arise, 
particularly in oncology trials, due to the possibility that biomarker 
screening might fail requiring a second biopsy. Obtaining a second bi-
opsy can be painful, have associated risks and be difficult be obtain if 
patients are not well enough. In such cases, it may or may not be 
appropriate to include a trial option for non-stratified patients 
(including those with failed biopsies), particularly if biomarker 
screening is invasive or has a high failure rate. 
Effective communication with patients is also fundamental to ensure 
a clear understanding of the purpose of biomarker trials, and whilst they 
are often about targeting treatments to patients most likely to benefit, 
they can also be about trying to avoid treatments in patients who are 
unlikely to benefit from them. This may aid acceptance by those not 
being offered an experimental treatment based on their biomarker 
profile. Whilst on the surface personalizing treatment may sound like the 
optimal solution, it should not be communicated as if a treatment will 
definitely work in a patient with given biomarker status, but rather is an 
approach that will mean it is potentially more likely to work. It is also 
essential that patients understand that being screened for a biomarker 
does not guarantee they will be eligible for the trial, since they will often 
have to meet additional eligibility criteria. Further, there may be a delay 
in meeting eligibility criteria such that the trial is closed before the 
patient can be recruited. 
An additional ethical challenge can arise in trials, where genetic 
markers are being assessed, and susceptibility to certain other diseases 
are uncovered – so-called ‘incidental’ findings, and this is a subject of 
much debate [16,17]. From the patient’s perspective, in theory this issue 
can be covered in the informed consent process by allowing them to 
opt-in or opt-out of information on incidental findings. In reality how-
ever, the issue is far more complex since making a truly informed de-
cision would require the patient to have an extensive amount of 
specialist genetic counselling for numerous conditions unrelated to the 
primary reason for the genetic test. Further, it can pose a moral dilemma 
to those involved in conducting the trial. Whilst there are clear advan-
tages arising from incidental findings which can be actioned medically, 
there is a risk of false positive findings, and knowledge of future disease 
risk and the anxiety it brings can do more harm than good in asymp-
tomatic patients [17]. Additionally, from the patients’ perspective, they 
can often mistakenly assume that having certain mutations in their 
tumour means an increased risk of disease in relatives. Hence, more 
careful communication is needed in order to clarify the difference be-
tween mutations in a tumour and germline mutations, and which type 
they are being tested for. 
In summary, several ethical and regulatory challenges can arise 
ranging from a lack of consistency surrounding administrative proced-
ures to issues relating to communications with patients. It is essential 
that accurate information about biomarker-guided trials is communi-
cated to all relevant stakeholders so that they are aware of the charac-
teristics and advantages of such trials. 
3.3. Recruitment 
Uncertainty in recruitment rates, especially in trials that include rare 
biomarker groups, can be a major dilemma. The prediction of recruit-
ment rate into umbrella trials can be difficult due to several factors. One 
of these factors is uncertainty surrounding the estimated prevalence of 
each biomarker since this might not be accurately known at the design 
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stage. The uncertainty is greater in the case of trials that evaluate mul-
tiple biomarkers as overlapping groups can occur (i.e. a single patient 
positive for multiple biomarkers). Another contributing factor is that the 
failure rate of laboratory diagnostic biopsies in the technology hubs is 
difficult to predict. The funders and sponsors regularly question whether 
the achieved recruitment rate is close to that projected. Recalculations 
and protocol amendments may be required, which can often be more 
complex for biomarker-guided trials than for a traditional trial. Hence, a 
more flexible methodology is needed for predicting recruitment rate for 
these trials. Indeed, a more sophisticated statistical approach to pre-
diction that incorporates the uncertainties could be considered in order 
to provide a realistic range for expected recruitment into each biomarker 
group. 
Recruitment issues can be patient related or researcher related. From 
the patients’ perspective, if there is considerable time between a patient 
undergoing molecular screening and being approached about a treat-
ment trial they may be fatigued or experiencing toxicity symptoms after 
first line treatment, or their disease may have progressed, or they may 
simply not be interested in the new drug and would like to take a break 
from treatment. In addition, having complex tissue sampling (manda-
tory fresh biopsies) is always a challenge for recruitment since some 
patients would prefer to not have such invasive testing, and in addition 
due to the complexity sampling may take some time in which case a 
patient’s status and ability to participate may have changed. 
From the researchers’ perspective, slow trial set up due to the 
necessary sample collection and processing procedures that need to be 
established not only delays recruitment but might also lead to study sites 
losing their enthusiasm. In turn, this may affect the motivation of 
commercial partners to get involved. Further problems can arise when it 
is difficult to predict recruitment timelines, as seen in the TOPARP trial. 
It was difficult to accurately predict recruitment as there was a “lead 
site” effect at the Chief Investigator’s (CI) site. Due to a change in the 
formulation of the novel agent it was necessary to initially only recruit 
patients at the lead site for safety reasons. Complex sampling collection 
and processing requirements took external sites longer to establish and 
as a consequence the management of collaborators’ expectations (fun-
ders, sites, investigator and commercial partners) was challenging. 
Additionally a higher screening failure rate was noted at external sites, 
potentially due to the population of patients seen. Therefore, screening 
activity at site was increased along with activity at the central lab/CTU. 
Due to the time to deliver biomarker results to sites, sites tested patients 
for the biomarker earlier in the patient pathway than anticipated leading 
to a pool of biomarker patients waiting to be eligible for the trial and 
increased activity at the central laboratory and CTU. 
In addition, the dropout rate from trials can be significant, particu-
larly where trials involve patients with rapidly progressing disease. For 
example, in the NLMT trial where patients with advanced lung cancer 
were considered, genetic profiling was undertaken on diagnostic sam-
ples whilst the patients were undergoing standard first line treatment 
and by the time they were ready to enter the trial after progression from 
first line treatment, the condition of many had deteriorated too much for 
them to participate. It is not uncommon for a patient to have died before 
the results are available. Even if they are still alive, the patient’s con-
dition may have deteriorated or they may have decided they no longer 
want to be involved in the trial. Risk of dropout is further increased since 
once someone has been recruited, the schedule of trial assessments can 
be too demanding, and the patient may decide to take the simpler option 
of not partaking in the trial. Further, receiving a novel therapy may 
require travel to a more distant location and those with advanced dis-
ease may find it challenging to do so. The likelihood of dropping out can 
be reduced by ensuring rapid turnaround times for biomarker test re-
sults, which allow treatment to begin more quickly. 
To summarize, given the multiple factors impacting how likely pa-
tients will be identified, recruited and retained in a biomarker-guided 
trial, estimating an accurate rate of recruitment will always be diffi-
cult. It is suggested, therefore, that well-designed pilot and feasibility 
studies are undertaken prior to trial commencement to ensure a more 
accurate understanding of recruitment rate as well as a smoother and 
more rapid process of site set-up. It is often more attractive to incor-
porate a feasibility study into the main trial, with in-built go/no go 
criteria, so that starting the trial itself is not unduly delayed. Labora-
tories should also be sufficiently equipped and efficient to deal with 
rapid biomarker analysis turnaround. It is important to note that the 
trials discussed here, and their associated recruitment challenges are 
some of the first of their kind, and that experience of working on these 
and other similar trials will also guide us in predicting more accurate 
and achieving better recruitment rates in future, as well as ease the 
process of site set-up. 
3.4. Monitoring samples and laboratories 
It is expected that good internal audit trails are in place within lab-
oratories undertaking biomarker assessment for clinical trials, however 
logistical problems can occur in the transfer of results from laboratory to 
CTU. Often, results for exploratory biomarkers are batched with hun-
dreds, or thousands of biomarker results transferred at a time, so it is 
important to agree on procedures for transferring the data accurately 
before trial commencement. Problems can arise when not all laboratory 
staff are trained in trials related GCP (Good Clinical Practice) and this is 
important to ensure that there is a sufficient audit trail and no breaches 
in confidentiality of biomarker data. Therefore, it is important that 
laboratories have a good understanding of GCP requirements. 
Tracking patient samples requires a significant amount of work and 
coordination, and is often more complex than what is typically required 
from laboratory information management systems. For example, a first 
sample may be received and there might be insufficient tumour, 
meaning that another sample has to be requested. A full audit trail is 
required to ensure that the correct biomarker test result is used in the 
analysis. A significant amount of data cleaning is also typically required. 
In terms of the handling and tracking of samples, local research 
nurses, pathologists, laboratory staff as well as the CTU will be involved. 
In FOCUS4, a challenge arose with sample management in that patients 
could be registered up to 12 weeks after starting their first line chemo-
therapy meaning that a fast turnaround was required at the laboratories 
to ensure biomarker results were received before the patients had ended 
their 16 weeks of first line therapy. Further difficulties arise when the 
tissue obtained is inadequate or is not viable and further requests for 
samples need to be made back to the original hospital pathology 
departments. 
To ensure optimal efficiency, it is recommended that lots of samples 
are batched up to be sent all at once instead of using additional resources 
on several small runs. However, this can lead to problems when lower 
than anticipated recruitment leads to further delays as labs wait for 
enough samples to justify running a batch. It is also not practical in 
smaller trials where a quick turnaround or ‘fresh’ samples are essential. 
Examples of additional problems with sample management were 
observed in FOCUS4, including resolution of pathology number dis-
crepancies and failure to send GCP compliant documents to the CTU. 
Further, in NLMT, a particular challenge arose with the lab reports. 
Here, the genetic result reports did not state which strata in the trial the 
patient was eligible for, and thus the CTU personnel were required to 
read the complex reports and determine the appropriate treatment 
allocation for the patient. Not only was this an additional burden on CTU 
staff but required rigorous procedures to minimise the risk of error, 
including sign off of all allocations by the CI. 
Another challenge associated with biomarker analysis is that science 
is advancing rapidly with many new opportunities arising in biomarker 
assessment. It is recommended that a separate lab manual is used 
outside the protocol in order to minimise any associated protocol 
amendments. 
In terms of ensuring completeness and quality of tissue samples 
received, communication and collaboration between clinicians and 
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laboratory staff should be strengthened to ensure that samples are taken, 
stored and sent off in accordance with the protocol. In addition, the 
CTU’s central trial monitoring capabilities should be utilised to ensure 
efficient sample tracking. Strong collaboration between the CTU and the 
laboratory staff is essential given how dependent the success of a 
biomarker-guided trial is on accurate and timely delivery of lab results. 
3.5. Biomarker assessment 
One major challenge during biomarker assessment can arise when 
samples are heterogeneous. This misclassification problem is less of an 
issue when patients are randomized but it can lead to a dilution of any 
observed treatment effects. Biomarker misclassification therefore rep-
resents a challenge within biomarker-guided trials, and further sensi-
tivity analyses may be needed to address its effect on the trial result. 
Another issue is that whilst it is relatively straightforward to look for 
the presence or absence of a particular mutation in a particular gene, it is 
much more difficult to be able to say with confidence that a gene is 
normal in order to be able to classify a patient. Therefore, the analytical 
validity of a biomarker in terms of sensitivity and specificity is a chal-
lenging but very important issue and understanding the accuracy of an 
assay is a necessary consideration. If a sample fails completely, it is easy 
to class it as failed; if there is a partial fail, this represents a difficult 
result to handle and it can be difficult to classify a patient based upon the 
result. 
Challenges can arise when a laboratory is required to change the 
staining machine and assay during the course of the trial. In this case it is 
likely that measurements taken prior to the change may need to be 
repeated using the newer technology or at a minimum calibration of the 
results investigated. Apart from the significant cost implications, it is 
also necessary to appropriately consider cases where the new result 
differs from the previous one. Conducting an analysis that is stratified by 
the date the assay measurement changed may be an alternative way of 
handling these sorts of biomarker adaptations during the trial. 
3.6. Data sharing issues 
When a pharmaceutical company is involved in a trial, along with the 
clinical study report it may be expected that the trial data will be shared 
with the company at the end of the trial, within a data sharing frame-
work, and this will be detailed in the contract. However, in early phase 
trials companies may want data to be shared in real time or at least at 
periodic intervals (e.g., to guide business decisions) during the trial. 
Current consensus suggests that this is not good practice for phase III 
trials. For single arm phase II trials which are more exploratory in nature 
opinions differ as to its merits, especially when treatments are being 
evaluated using a response endpoint. One argument against this type of 
data sharing during the trial is that historically, if you questioned why a 
phase II trial had failed, one reason was that the clinicians or CIs were 
too selective in picking their patients when they had a fixed threshold of 
responders to reach to call it a success (e.g., selecting patients more 
likely to respond creating a distorted cohort of patients in the latter part 
of the trial). Sharing data during the trial could result in such situations 
arising again. 
Further, whilst decisions in terms of the closure of strata are the 
responsibility of the trial oversight committees, pharmaceutical com-
panies may wish to be involved in the decision making process. 
Whilst data sharing requests from pharmaceutical companies are 
likely to be common in biomarker-guided trials, differing viewpoints in 
terms of how and when data should be shared can be particularly 
challenging for the trial management team. To ensure that good re-
lations are maintained with all interested parties, it is recommended that 
a clear data sharing policy and common data standards are developed 
and agreed at the point of contract negotiation, prior to trial outset, with 
all aspects of decision-making explicitly stated as the remit of the in-
dependent trial oversight committee. 
3.7. Resources 
In terms of clinical trials unit (CTU) management ensuring the 
availability of appropriate resources is a challenge. Biomarker-guided 
trials require adequate funding for dedicated personnel. The 
complexity of the required IT support is frequently underestimated and 
essential for biomarker-guided trials. The complexity of the Case Report 
Forms (CRF) is a particular challenge, since the data required often 
varies between strata. Hence, there is a need for several different case 
report forms equivalent to having many separate trials but with the 
additional burden of needing a more sophisticated over-arching data-
base structure. Protocol amendments lead to additional problems due to 
the fact that for just one amendment (e.g. an additional medical 
assessment), all CRFs require modification. The consequences of 
needing separate CRFs for different comparisons were observed in the 
FOCUS4 trial. The trial uses electronic data capture (eDC) where local 
site staff enter data directly into the database. When the trial was first 
set-up, it opened with only one molecular comparison and a single non- 
stratified comparison. The aim was to have all cohorts eventually in one 
main database, however, this has proven difficult and it was decided to 
include future comparisons in separate databases, meaning that sites 
have to open a number of different databases to enter data for their 
FOCUS4 patients rather than just one. 
Furthermore, administrative support for tasks such as preparing site 
packs is often underestimated, and the need for collaboration between a 
clinical trials unit and biomarker labs adds further pressure onto re-
sources. Challenges associated with such collaboration relate to labo-
ratory agreements (e.g., impact on data sharing) and the processes for 
tracking, blinding and pseudo-anonymization of samples. In addition, 
specialist biomarker expertise is required, something which is not 
typically available within a CTU. 
More complex work is also needed when adding new treatment 
groups to platform trials or making other adaptations to a trial. Several 
issues need to be considered at that time; in essence incorporating a new 
treatment group in a master protocol is equivalent to setting up a new 
trial, including protocol writing and case report forms development, 
database development, setting up of contracts, drugs supply etc. while 
recruitment, co-ordination and data collection for existing treatment 
groups continues. Further, whilst existing systems and processes may 
work with an initial small number of groups, they may not work as well 
with a much larger number of groups, and it is therefore difficult to 
predict level of resource upfront, leading to inefficiencies down the line. 
POETIC faced several challenging issues, many of those relating to 
the need to extend the clinical trials culture across multidisciplinary 
teams involved at cancer diagnosis, and the integration of research 
protocols into busy clinics. For these reasons, a variety of pathways 
(different fresh tissue collection options) as well as different types of 
tissue (availability of biological and non-biological centres) were 
considered. 
To summarize, the resources required for efficient management of a 
biomarker-guided trial should not be under-estimated and clinical trial 
units in particular need to ensure that they are prepared in particular for 
the administrative burdens that come with such trials, and adequately 
cost them into any funding applications. 
4. Discussion 
At our workshop ‘Biomarker-guided trials: challenges in practice’ 
several practical challenges were considered:  
- Funding issues, including higher resources due to typical complexity 
of biomarker-guided trials, difficulties in making accurate cost pre-
dictions at the outset, confusion over who should meet biomarker 
testing costs and the need for sharing of knowledge and experience 
between researchers and funders’ regarding the implications of using 
such designs. 
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- Ethical and regulatory issues, including uncertainty about whether 
amendments require new approvals, the need to maintain a collab-
orative relationship and effective communication with HRA and 
regulators and issues relating to communications with patients.  
- Recruitment issues such as the difficulty in predicting an accurate 
recruitment rate, delays in setting up sites, and unknown patient 
dropout rates. 
- Issues arising in the tracking and monitoring of samples and labo-
ratories when not all laboratory staff are GCP trained, the need for 
efficient sample processing and tracking, dealing with changing 
technologies, challenges of biomarker misclassification and the need 
to establish effective communication and collaboration between 
clinicians and laboratory staff to address current challenges.  
- Issues regarding data sharing agreements, particularly when working 
in collaboration with pharmaceutical companies.  
- Resourcing issues, including underestimation of the extent of IT and 
administrative support required, and of the complexity of databases 
and CRFs. 
Although many of the challenges discussed relate to the more com-
plex biomarker-guided trials such as umbrella trials, similar challenges 
can appear in biomarker-guided clinical trials more generally. Likewise, 
we acknowledge that some of the challenges identified are equally 
relevant to more complex trials irrespective of whether they incorporate 
biomarkers or not (e.g. predicting the cost of adding/removing arms, 
approving amendments, CTU resource issues), whilst others are specific 
to biomarker-guided trials (e.g. predicting recruitment rates when 
biomarker prevalence unknown, ethical issues related to communi-
cating results of biomarker tests, sample processing and laboratory 
challenges). 
Despite the aforementioned challenges, the biomarker-guided trials 
discussed within this report represent successful research projects using 
novel designs, which will hopefully inform future practice. NLMT, for 
example, provides a great opportunity for widespread national collab-
oration with leaders from the lung cancer community within academia, 
the health service and the pharmaceutical industry, and direct collabo-
ration with CRUK. It promises to make a real contribution to the 
knowledge on precision medicine by testing new drugs tailored to a 
specific biomarker-defined subgroup. 
Further, the FOCUS4 trial, uses an efficient Multi-Arm, Multi-Stage 
(MAMS) design which has proved to be particularly efficient in the 
mCRC disease setting where the progression-free survival (PFS) event 
rate is high and interim analyses are triggered quickly. Its other suc-
cesses include having a strong collaborative trial management group 
with a very engaged overall CI, the use of different CIs for each com-
parison, early engagement with the Research Network, clear protocol 
structure and nomenclature as well as the single regulatory and ethics 
approvals. 
TOPARP demonstrated anti-tumour activity of olaparib in patients 
with advanced CRPC (Mateo J et al., N Engl J Med 373 (18):1697-708) 
and was the first molecular treatment stratification in metastatic cas-
trate resistant prostate cancer (mCRPC). A successful collaboration be-
tween ICR, AstraZeneca and Cancer Research UK (National Cancer 
Research Network Collaboration) led to the FDA granting olaparib 
breakthrough therapy designation based largely on the results of 
TOPARP-A. 
EU-PACT provides an example of an international, multi-site trial 
which, due to its pragmatic approach and adoption of the biomarker- 
strategy design allowed the improved treatment outcomes from using 
a biomarker-guided approach to prescribing warfarin to be demon-
strated. This has led to a subsequent matched-cohort study which 
demonstrated the successful implementation of the biomarker-guided 
approach into clinical practice [18], and a trial based on EU-PACT is 
currently being planned in Africa to test the clinical utility of a per-
sonalised approach to warfarin dosing in low-resource settings. 
To conclude, the examples of biomarker-guided trials considered 
here demonstrate the real benefits of adopting such designs, despite the 
teething problems resulting from using such novel methodologies. 
However, the significant investments required to successfully conduct 
such trials should not be underestimated, and it is imperative that the 
practical challenges they bring for clinicians, laboratories, regulators, 
academia, industry and patients as outlined above should be acknowl-
edged and addressed at the outset. As the need for trials in stratified 
medicine increases however, it is anticipated that through experience 
stakeholders will become more familiar with the designs, and the pro-
cedures involved in conducting and managing them will evolve and 
adapt accordingly. It is important therefore that the knowledge gained 
by those with experience of biomarker-guided trials is communicated to 
the wider research community such that all stakeholders are educated 
about the complex issues that biomarker-guided clinical trials face and 
recommendations for how they may be overcome. 
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